<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37271712</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-114X</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical therapeutics</Title><ISOAbbreviation>Clin Ther</ISOAbbreviation></Journal><ArticleTitle>Health Care Costs With Sustained Oral Corticosteroid Use in Systemic Lupus Erythematosus.</ArticleTitle><Pagination><StartPage>619</StartPage><EndPage>626</EndPage><MedlinePgn>619-626</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinthera.2023.04.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0149-2918(23)00152-2</ELocationID><Abstract><AbstractText Label="PURPOSE">The goal of this study was to compare health care costs, health care resource utilization, and adverse events associated with sustained oral corticosteroid (OCS) use versus no OCS use in systemic lupus erythematosus.</AbstractText><AbstractText Label="METHODS">This retrospective cohort study used claims data (January 1, 2006-July 31, 2019) from patients with systemic lupus erythematosus aged &#x2265;5 years with &#x2265;24 months of continuous enrollment. Health care costs, health care resource utilization, and OCS-related adverse events were assessed. The sustained OCS cohort (defined as &#x2265;12 months of continuous OCS use) was divided into exposure categories based on the number of 6-month classification periods with &gt;5 mg/d OCS (0, 1-2, or 3-4).</AbstractText><AbstractText Label="FINDINGS">Of the 6234 patients in the sustained OCS use cohort, there were 1587 (25.5%) patients with 0 periods of &gt;5 mg/d OCS use, 2087 (33.5%) patients with 1 to 2 periods of &gt;5 mg/d OCS use, and 2560 (41.1%) patients with 3 to 4 periods of &gt;5 mg/d OCS use; the no OCS use cohort included 7828 patients. Adjusted health care cost differences (95% CIs) were significantly greater for patients with 0, 1 to 2, and 3 to 4 periods of OCS use &gt;5 mg/d versus the no OCS use cohort ($7774 [5426-10,223], $21,738 [18,898-25,321], and $30,119 [26,492-33,774], respectively). A higher proportion of patients in all OCS exposure categories required health care resource utilization (&#x2265;99.7% vs 93.4%) and experienced OCS-related adverse events (94.3%-96.8% vs 82.6%) versus the no OCS use cohort, with more periods of OCS use &gt;5 mg/d associated with increased health care resource utilization and adverse events.</AbstractText><AbstractText Label="IMPLICATIONS">Sustained OCS use in systemic lupus erythematosus was associated with high economic burden, health care resource utilization, and OCS-related adverse events. These data highlight the need for health care providers to carefully consider OCS use in systemic lupus erythematosus.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Shirley P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>GSK, US Value Evidence and Outcomes, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DerSarkissian</LastName><ForeName>Maral</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Analysis Group, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Yuqian M</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Analysis Group, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duh</LastName><ForeName>Mei Sheng</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Analysis Group, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Min-Jung</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Analysis Group, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benson</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Analysis Group, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vu</LastName><ForeName>Jensen Duy</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Analysis Group, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Averell</LastName><ForeName>Carlyne M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>GSK, US Value Evidence and Outcomes, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Christopher F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>GSK, US Value Evidence and Outcomes, Durham, North Carolina, USA. Electronic address: christopher.f.bell@gsk.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Ther</MedlineTA><NlmUniqueID>7706726</NlmUniqueID><ISSNLinking>0149-2918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="Y">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">burden of disease</Keyword><Keyword MajorTopicYN="N">economic burden</Keyword><Keyword MajorTopicYN="N">oral corticosteroids</Keyword><Keyword MajorTopicYN="N">sustained corticosteroid use</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest Dr Huang and Ms Averell were employees of GSK and held stocks and shares in the company. Dr Huang is an employee of Seagen, Inc. Dr DerSarkissian, Dr Duh, and Mr Benson are employees of Analysis Group. Dr Wang, Ms Gu, and Mr Vu are former employees of Analysis Group. Analysis Group received research funding from GSK to conduct this study. Mr Bell is an employee of GSK and holds stocks and shares in the company. GSK was involved in the study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>4</Day><Hour>22</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37271712</ArticleId><ArticleId IdType="doi">10.1016/j.clinthera.2023.04.013</ArticleId><ArticleId IdType="pii">S0149-2918(23)00152-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>